We’re addressing an unmet medical need says founder

Severe impact on global economies

”NEUROPATHIC PAIN has a severe impact not only on individual sufferers’ physical and mental health but also on national economies . In the US, almost 20% of adults suffer from chronic pain (2016) with an estimated annual cost of $560 billion in direct medical costs, lost productivity, and disability programs.

Existing chronic pain drugs are only partly effective, and only for some patients, and they are associated with significant side effects. Our mission is to develop safe and effective medicines for neuropathic pain treatment.

Our team has taken our lead candidate PN6047 successfully through pre-clinical studies and it is now engaged in first in man clinical studies. This is a great achievement for a small Biopharma company. Today, I am totally convinced that we can deliver safe and effective medicine for the treatment of chronic, neuropathic pain”.

‍‍

Bengt von Mentzer, founder and chief scientific advisor

‍

Latest news

View all

April 17, 2026

Watch PharmNovo at LSX in Lisbon

Take the opportunity to listen to Per von Mentzer, CEO, presenting PN6047 at the LSX World Europe congress in Lisbon, March 2026. Learn how PharmNovo is shaping a new approach to pain relief with the goal to prove that powerful pain treatment doesn’t have to come with the cost of addiction. Discover how the company’s lead candidate PN6047, delivers effective pain relief without activating the mu-opioid receptor and avoiding the addiction risks associated with conventional opioids. The Phase II-ready Delta Opioid Receptor Agonist (DORA) with first-in-class potential, PN6047 represents a safer, non-addictive approach targeting a neuropathic pain market that is expected to double until 2033 and reach 13 bEUR.

April 9, 2026

Capsules ready for Phase IIa Study

PharmNovo is pleased to announce that that the company has completed drug product manufacturing for its lead candidate PN6047. This is an important milestone as the company prepares for its upcoming Phase IIa proof-of-concept study in neuropathic pain.

January 30, 2026

Welcome on Board

As the company prepares for the next phase of clinical development, the new Board composition strengthens our strategic capabilities ahead of Phase II development of our lead candidate, PN6047.

November 26, 2025

Endowed Chair awarded

We are delighted to share that Professor Amynah Pradhan has been awarded a prestigious Endowed Chair at Washington University, where she now serves as the Russell D. and Mary B. Shelden Professor of Anesthesiology.